[go: up one dir, main page]

PL3337502T3 - Stabilna formulacja anty-ifnar1 - Google Patents

Stabilna formulacja anty-ifnar1

Info

Publication number
PL3337502T3
PL3337502T3 PL16837818T PL16837818T PL3337502T3 PL 3337502 T3 PL3337502 T3 PL 3337502T3 PL 16837818 T PL16837818 T PL 16837818T PL 16837818 T PL16837818 T PL 16837818T PL 3337502 T3 PL3337502 T3 PL 3337502T3
Authority
PL
Poland
Prior art keywords
ifnar1
formulation
stable anti
stable
ifnar1 formulation
Prior art date
Application number
PL16837818T
Other languages
English (en)
Inventor
Roberto Depaz
Natalie DEJESUS
Jared BEE
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58052002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3337502(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL3337502T3 publication Critical patent/PL3337502T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
PL16837818T 2015-08-19 2016-08-18 Stabilna formulacja anty-ifnar1 PL3337502T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207164P 2015-08-19 2015-08-19
PCT/US2016/047506 WO2017031288A1 (en) 2015-08-19 2016-08-18 Stable anti-ifnar1 formulation
EP16837818.0A EP3337502B1 (en) 2015-08-19 2016-08-18 Stable anti-ifnar1 formulation

Publications (1)

Publication Number Publication Date
PL3337502T3 true PL3337502T3 (pl) 2021-01-11

Family

ID=58052002

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20174805.0T PL3769781T3 (pl) 2015-08-19 2016-08-18 Stabilna formulacja anty-ifnar1
PL16837818T PL3337502T3 (pl) 2015-08-19 2016-08-18 Stabilna formulacja anty-ifnar1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20174805.0T PL3769781T3 (pl) 2015-08-19 2016-08-18 Stabilna formulacja anty-ifnar1

Country Status (25)

Country Link
US (1) US10125195B2 (pl)
EP (3) EP3337502B1 (pl)
JP (4) JP6720293B2 (pl)
KR (4) KR20240090616A (pl)
CN (1) CN107921109A (pl)
AU (3) AU2016308262C1 (pl)
BR (1) BR112018002196A8 (pl)
CA (1) CA2995222C (pl)
CY (2) CY1123657T1 (pl)
DK (2) DK3337502T3 (pl)
ES (2) ES2818229T3 (pl)
FI (1) FI3769781T3 (pl)
HK (1) HK1256195A1 (pl)
HR (2) HRP20230463T1 (pl)
HU (2) HUE061985T2 (pl)
IL (1) IL257279B2 (pl)
LT (2) LT3337502T (pl)
PL (2) PL3769781T3 (pl)
PT (2) PT3337502T (pl)
RS (2) RS60773B1 (pl)
RU (1) RU2731737C2 (pl)
SG (1) SG10202106970XA (pl)
SI (2) SI3769781T1 (pl)
SM (2) SMT202300176T1 (pl)
WO (1) WO2017031288A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125195B2 (en) 2015-08-19 2018-11-13 Astrazeneca Ab Stable anti-IFNAR1 formulation
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20200061015A1 (en) * 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
DK4058060T3 (da) * 2019-11-11 2025-03-17 Astrazeneca Ab Type i-interferon-hæmning ved systemisk lupus erythematosus
CN115667309A (zh) * 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
AU2021295605A1 (en) 2020-06-25 2023-02-16 Eli Lilly And Company Prevention of axonal damage using antibody binding to amyloid BETA 1-42
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
JP2024518735A (ja) * 2021-04-23 2024-05-02 アストラゼネカ・アクチエボラーグ 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療
CA3216390A1 (en) * 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of cutaneous lupus erythematous
CN117157099A (zh) * 2021-04-23 2023-12-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
CA3216387A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Anti-ifnar1 dosing regime for subcutaneous injection
WO2022238479A1 (en) * 2021-05-12 2022-11-17 Astrazeneca Ab Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
CN113527490B (zh) * 2021-07-13 2022-03-01 江苏荃信生物医药股份有限公司 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂
AU2022317215A1 (en) 2021-07-27 2024-02-29 Astrazeneca Ab Treatment of lupus
AU2022359684A1 (en) * 2021-10-04 2024-05-09 Astrazeneca Ab Treatment of lupus
EP4422674A1 (en) * 2021-10-29 2024-09-04 Intas Pharmaceuticals Ltd. Stable lyophilized formulation of an anti-alpha 4beta7 antibody
TW202337497A (zh) * 2022-02-18 2023-10-01 中國大陸商重慶明道浩悅生物科技有限公司 鼻內調配物及抗sars-cov-2棘蛋白抗體
IN202221038828A (pl) * 2022-07-06 2024-01-12
WO2024079241A1 (en) 2022-10-13 2024-04-18 Astrazeneca Ab Treatment of lupus
WO2024241156A1 (en) 2023-05-19 2024-11-28 Astrazeneca Ab Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
CN101001878B (zh) * 2004-06-21 2012-09-26 米德列斯公司 干扰素α受体1抗体及其用途
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
CA2692165A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
KR101666229B1 (ko) * 2008-02-08 2016-10-14 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
BRPI0921845A2 (pt) * 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
SG11201400815TA (en) 2011-10-12 2014-09-26 Ascendis Pharma Ophthalmology Division As Prevention and treatment of ocular conditions
CN104023748B (zh) * 2011-10-28 2018-03-02 诚信生物公司 含有氨基酸的蛋白质制剂
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
RU2015119547A (ru) * 2012-10-25 2016-12-20 МЕДИММЬЮН, ЭлЭлСи Стабильный низковязкий состав с антителом
AU2014265624B2 (en) 2013-05-15 2019-09-12 Medimmune Limited Purification of recombinantly produced polypeptides
IL312865B1 (en) * 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
US20160250329A1 (en) * 2013-10-29 2016-09-01 Albumedix A/S Antibody composition
AU2015310879A1 (en) 2014-09-03 2017-03-02 Medimmune Limited Stable anti-IL-4R-alpha antibody formulation
WO2016109822A1 (en) 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
US10125195B2 (en) 2015-08-19 2018-11-13 Astrazeneca Ab Stable anti-IFNAR1 formulation

Also Published As

Publication number Publication date
EP3769781A1 (en) 2021-01-27
HUE061985T2 (hu) 2023-09-28
CN107921109A (zh) 2018-04-17
AU2016308262B2 (en) 2020-04-30
AU2020203306C1 (en) 2022-03-31
IL257279A (en) 2018-03-29
EP4233892A2 (en) 2023-08-30
RS60773B1 (sr) 2020-10-30
AU2016308262A1 (en) 2018-03-08
SI3769781T1 (sl) 2023-06-30
KR20200119916A (ko) 2020-10-20
BR112018002196A2 (pt) 2019-04-30
SMT202000483T1 (it) 2020-11-10
EP3337502A1 (en) 2018-06-27
KR20180041173A (ko) 2018-04-23
DK3337502T3 (da) 2020-09-14
AU2020203306B2 (en) 2021-09-09
DK3769781T5 (da) 2024-08-19
AU2016308262C1 (en) 2022-04-21
JP2022066345A (ja) 2022-04-28
KR20240090616A (ko) 2024-06-21
CA2995222C (en) 2021-07-13
SMT202300176T1 (it) 2023-07-20
KR102669174B1 (ko) 2024-06-10
JP2020158527A (ja) 2020-10-01
JP7035119B2 (ja) 2022-03-14
RU2731737C2 (ru) 2020-09-08
AU2021257915A1 (en) 2021-11-18
RU2018107725A (ru) 2019-09-19
CA2995222A1 (en) 2017-02-23
BR112018002196A8 (pt) 2021-05-04
US20170051066A1 (en) 2017-02-23
DK3769781T3 (da) 2023-06-19
PT3769781T (pt) 2023-06-19
HUE051862T2 (hu) 2021-03-29
EP3337502A4 (en) 2019-01-23
HRP20230463T1 (hr) 2023-07-21
LT3337502T (lt) 2020-09-25
WO2017031288A1 (en) 2017-02-23
JP2018523676A (ja) 2018-08-23
ES2818229T3 (es) 2021-04-09
IL257279B2 (en) 2023-04-01
HRP20201297T1 (hr) 2020-11-27
US10125195B2 (en) 2018-11-13
JP2024161043A (ja) 2024-11-15
SG10202106970XA (en) 2021-07-29
RU2018107725A3 (pl) 2019-10-02
FI3769781T3 (fi) 2023-06-07
SI3337502T1 (sl) 2020-10-30
ES2947488T3 (es) 2023-08-10
CY1126062T1 (el) 2023-11-15
EP4233892A3 (en) 2023-10-25
KR20220127378A (ko) 2022-09-19
HK1256195A1 (zh) 2019-09-13
KR102168005B1 (ko) 2020-10-21
IL257279B (en) 2022-12-01
EP3769781B1 (en) 2023-04-19
LT3769781T (lt) 2023-06-12
JP6720293B2 (ja) 2020-07-08
PL3769781T3 (pl) 2023-07-17
EP3337502B1 (en) 2020-06-24
AU2020203306A1 (en) 2020-06-11
RS64263B1 (sr) 2023-07-31
CY1123657T1 (el) 2022-03-24
PT3337502T (pt) 2020-09-23

Similar Documents

Publication Publication Date Title
HK1256195A1 (zh) 穩定的抗ifnar1配製品
GB201407934D0 (en) Formulation
GB201513010D0 (en) Novel formulation
GB201514758D0 (en) Formulation
GB201407384D0 (en) Formulation
PT3173071T (pt) Formulação de maropitant
GB201608356D0 (en) Formulation
IL248835A0 (en) A preparation of ciritinib
IL251362A0 (en) formulation
GB201521771D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201511301D0 (en) Formulation
GB201707615D0 (en) Formulation
PL3559185T3 (pl) Preparat nabłyszczający
GB201514014D0 (en) Formulation
GB201609925D0 (en) Formulation
GB201504662D0 (en) Formulation
GB201602048D0 (en) Formulation
GB201508527D0 (en) Novel formulation
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201412754D0 (en) Formulation